Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Neil A. Bailey, Laurie Pearson(Tufts Medical Center), Brian T. Hill(Cleveland Clinic), Allison Winter(Cleveland Clinic), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Alan P Skarbnik(Novant Health), AnnaLynn M. Williams(University of Rochester), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Amy A. Kirkwood(Cancer Research UK), John N. Allan(Cornell University), Colleen Dorsey(Memorial Sloan Kettering Cancer Center), Ryan Jacobs(Levine Cancer Institute), Charlene Kabel(Memorial Sloan Kettering Cancer Center), Danielle M. Brander(Duke University), Hannah Morse(Memorial Sloan Kettering Cancer Center), Mazyar Shadman(University of Washington), Toby A. Eyre(Oxford University Hospitals NHS Trust), Paul M. Barr(University of Rochester Medical Center), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Andrea Sitlinger(Duke Medical Center), Arun K. Singavi(Medical College of Wisconsin), Hande H. Tuncer(Tufts Medical Center), Sivraj Muralikrishnan(Dartmouth–Hitchcock Medical Center), Anna Schuh(University of Oxford), Chaitra S. Ujjani(Fred Hutch Cancer Center), Stephen J. Schuster(Hospital of the University of Pennsylvania), Christopher P. Fox(University of Nottingham), Bruce D. Cheson(Center for Cancer and Blood Disorders), Nirav N. Shah(Medical College of Wisconsin), André Goy(Hackensack University Medical Center), Chadi Nabhan(University of Chicago), Frederick Lansigan(Dartmouth College), John M. Pagel, Maryam Sarraf Yazdy(Georgetown University)
Clinical Cancer Research
April 19, 2019
Cited by 90


Related Papers